Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 278Magnetic Resonance Spectroscopy 233pembrolizumab 227Carboplatin 187Cisplatin 153Biopsy 148Cyclophosphamide 143Paclitaxel 133Nivolumab 122Gemcitabine 113Bevacizumab 104Radiotherapy 92Dexamethasone 86Pemetrexed 83fludarabine 77Fluorouracil 76Docetaxel 75Doxorubicin 74atezolizumab 71Radiation 71Leucovorin 70Rituximab 67Oxaliplatin 66venetoclax 61durvalumab 61Prednisone 60Vincristine 56Cetuximab 56Lenalidomide 54Etoposide 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphatic Irradiation × 30 days × Clear all
NCT06287944 2026-05-18

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1 Recruiting
15 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡